The DOI matches its Crossref record; 263 of the 263 references it cites were found in a registry or an index.
Pathogenesis, diagnostics, and therapeutics for Alzheimer's disease: Breaking the memory barrier
Open accessAbstract
Alzheimer's disease (AD) is the most common cause of dementia and accounts for 60-70 % of all cases. It affects millions of people worldwide. AD poses a substantial economic burden on societies and healthcare systems. AD is a progressive neurodegenerative disorder characterized by cognitive decline, memory loss, and impaired daily functioning. As the prevalence of AD continues to increase, understanding its pathogenesis, improving diagnostic methods, and developing effective therapeutics have become paramount. This comprehensive review delves into the intricate mechanisms underlying AD, explores the current state of diagnostic techniques, and examines emerging therapeutic strategies. By revealing the complexities of AD, this review aims to contribute to the growing body of knowledge surrounding this devastating disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Alzheimer's disease: the amyloid cascade hypothesis
Hardy, J. A., & Higgins, G. A. (1992) · Science · doi:10.1126/science.1566067 · Cited by 7,484
Nichols, E., Steinmetz, J. D., Vollset, S. E., Fukutaki, K., Chalek, J., Abd-Allah, F., Abdoli, A., Abualhasan, A., Abu-Gharbieh, E., Akram, T. T., et al. (2022) · The Lancet Public Health · doi:10.1016/s2468-2667(21)00249-8 · Cited by 5,575
Oxidative Stress: Harms and Benefits for Human Health
Pizzino, G., Irrera, N., Cucinotta, M., Pallio, G., Mannino, F., Arcoraci, V., Squadrito, F., Altavilla, D., & Bitto, A. (2017) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2017/8416763 · Cited by 4,837
Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B
Klunk, W. E., Engler, H., Nordberg, A., Wang, Y., Blomqvist, G., Holt, D. P., Bergström, M., Savitcheva, I., Huang, G., Estrada, S., et al. (2004) · Annals of Neurology · doi:10.1002/ana.20009 · Cited by 4,496
Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy
Liu, C.-C., Kanekiyo, T., Xu, H., & Bu, G. (2013) · Nature Reviews Neurology · doi:10.1038/nrneurol.2012.263 · Cited by 3,459
The neuropathological diagnosis of Alzheimer's disease
DeTure, M. A., & Dickson, D. W. (2019) · Molecular Neurodegeneration · doi:10.1186/s13024-019-0333-5 · Cited by 3,329 · cited 2×
“Improving early and accurate diagnostic methods is crucial for identifying individuals at the earliest stages of AD, facilitating early interventions and clinical trials (Deture and Dickson, 2019).”
BackgroundA protein factor essential for microtubule assembly
Weingarten, M. D., Lockwood, A. H., Hwo, S. Y., & Kirschner, M. W. (1975) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.72.5.1858 · Cited by 3,089
Krasemann, S., Madore, C., Cialic, R., Baufeld, C., Calcagno, N., El Fatimy, R., Beckers, L., O’Loughlin, E., Xu, Y., Fanek, Z., et al. (2017) · Immunity · doi:10.1016/j.immuni.2017.08.008 · Cited by 2,979
NLRP3 is activated in Alzheimer’s disease and contributes to pathology in APP/PS1 mice
Heneka, M. T., Kummer, M. P., Stutz, A., Delekate, A., Schwartz, S., Vieira-Saecker, A., Griep, A., Axt, D., Remus, A., Tzeng, T.-C., et al. (2013) · Nature · doi:10.1038/nature11729 · Cited by 2,898
Oxidative Stress: A Key Modulator in Neurodegenerative Diseases
Singh, A., Kukreti, R., Saso, L., & Kukreti, S. (2019) · Molecules · doi:10.3390/molecules24081583 · Cited by 2,254
Research works printed but not linked: 21
- Suzuki, 2023, Specific Mutations near the Amyloid Precursor Protein Cleavage Site Increase γ-Secretase Sensitivity and Modulate Amyloid-β Production, Int J. Mol. Sci. [Internet], 24, 24
- Fu, 2017, Role of microglial amylin receptors in mediating beta amyloid (Aβ)-induced inflammation, J. Neuroinflamm. [Internet], 14, 1
- Cha, 2012, Mitochondria-Specific Accumulation of Amyloid β Induces Mitochondrial Dysfunction Leading to Apoptotic Cell Death, PLoS One [Internet], 7
- Li, 2015, Different mechanisms of apolipoprotein E isoform–dependent modulation of prostaglandin E2 production and triggering receptor expressed on myeloid cells 2 (TREM2) expression after innate immune activation of microglia, FASEB J. [Internet]
- Mecca, 2022, Synaptic density and cognitive performance in, Alzheimer’S. Dis.: A PET Imaging Study [11C]UCB-J. Alzheimer’S. Dement. [Internet], 18, 2527
- Varghese, 2013, A review of neuroimaging biomarkers of Alzheimer’s disease., Neurol. Asia [Internet]
- Wu, 2022, Computed Tomography Density and β-Amyloid Deposition of Intraorbital Optic Nerve May Assist in Diagnosing Mild Cognitive Impairment and Alzheimer’s Disease: A 18F-Flutemetamol Positron Emission Tomography/Computed Tomography Study, Front Aging Neurosci. [Internet]
- Dumurgier, 2015, Cerebrospinal fluid amyloid-β 42/40 ratio in clinical setting of memory centers: A multicentric study, Alzheimers Res Ther. [Internet], 7, 1
- Hansson, 2023, Blood biomarkers for Alzheimer’s disease in clinical practice and trials, Nat. Aging, 3, 10.1038/s43587-023-00403-3 · DOI · Paper page
- Fabrizio, 2021, Artificial Intelligence for Alzheimer’s Disease: Promise or Challenge?, Diagn. [Internet], 10.3390/diagnostics11081473 · DOI
- Kumar, 2015, A review on Alzheimer’s disease pathophysiology and its management: An update, Vol. 67, 195
- Parums, 2021, Editorial: Targets for Disease-Modifying Therapies in Alzheimer’s Disease, Including Amyloid β and Tau Protein, Med Sci. Monit. [Internet]
- Vaz, 2020, Alzheimer’s disease: Recent treatment strategies, Vol. 887
- Tai, 2023, APNmAb005, an anti-tau antibody targeting synaptic tau oligomers, in Phase 1 for treatment of Alzheimer’s Disease and primary tauopathies, Alzheimer’S. Dement. [Internet], 10.1002/alz.076888 · doi:10.1002/alz.076888
- Ward, 2021, A phase 1 study of AL002 in healthy volunteers, Alzheimer’S. Dement. [Internet], 10.1002/alz.054669 · doi:10.1002/alz.054669
- Reich, 2018, Therapeutic Advantages of Dual Targeting of PPAR-δ and PPAR-γ in an Experimental Model of Sporadic Alzheimer’s Disease, J. Park. Dis. Alzheimers Dis., 5
- Armijo, 2021, Induced Pluripotent Stem Cell-Derived Neural Precursors Improve Memory, Synaptic Pathol. Abnorm. a Mouse Model Alzheimer’S. Dis., Vol. 10
- Hashmi, 2023, Exploring Methylene Blue and Its Derivatives in Alzheimer’s Treatment: A Comprehensive Review of Randomized Control Trials, Cureus [Internet], 10.7759/cureus.46732 · DOI
- Fariba, 2023, Deep Brain Stimul. Encycl. Mov. Disord., Three-Vol. Set. [Internet].
- Gordon, 2024, Vulnerability in Research: Basic Ethical Concepts and General Approach to Review. Ochsner Journal [Internet], 2020 Mar. 20 [cited
- Shah, 2023, Informed Consent, N. Engl. J. Med [Internet], 376, 863
Cited by
ALNasser, M. N., Alboraiy, G. M., Alsowig, E. M., & Alqattan, F. M. (2025) · Brain Sciences · doi:10.3390/brainsci15020215 · Cited by 35
“Early symptoms include memory problems, sleep issues, and mood disorders, progressing to difficulties in walking and communicating in later stages [4].”
Metadata
- Authors
- Kamatham, P. T., Shukla, R., Khatri, D. K., & Vora, L. K.
- Venue
- Ageing Research Reviews
- Publisher
- Elsevier BV
- Published
- 2024-11
- Volume
- 101
- Pages
- 102481
- ISSN
- 1568-1637 (ISSN-L)
- OpenAlex
- W4402169022
- Cited by
- 371
- References
- 263
- FWCI
- 28.43
- Type
- journal article
- Language
- en
- Open access
- hybrid
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- creativecommons.org/licenses/by/4.0/ (vor)
- Funders
- National Institute of Pharmaceutical Education and Research, Raebareli
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Pathogenesis, diagnostics, and therapeutics for Alzheimer's disease: Breaking the memory barrier. https://app.cochat.ai/papers/10.1016/j.arr.2024.102481
- The paper
- Kamatham, P. T., Shukla, R., Khatri, D. K., & Vora, L. K. (2024). Pathogenesis, diagnostics, and therapeutics for Alzheimer's disease: Breaking the memory barrier. Ageing Research Reviews. https://doi.org/10.1016/j.arr.2024.102481
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
